Cantor Fitzgerald Comments on PTC Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:PTCT)
PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) – Analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for PTC Therapeutics in a research report issued to clients and investors on Monday, July 1st. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($4.72) for the year, down […]
More Stories
DC Shooting Suspect Charged With Attempting to Assassinate Trump
By Stacy Robinson and Jackson Richman WASHINGTON—The Department of Justice has charged Cole Allen, the suspect in the White House...
United Arab Emirates to Leave OPEC Next Month
By Andrew Moran The United Arab Emirates said it is leaving OPEC and the broader alliance. “This decision follows a...
Improper US Government Payments Rose to $186 Billion in 2025: Watchdog
By Sylvia Xu Federal government agencies reported a total estimate of about $186 billion in improper payments in fiscal year...
US Homebuilders Lean on Incentives to Unload Homes in Challenging Market
By Panos Mourdoukoutas Homebuilder earnings reports released in recent days point to a challenging environment for the industry, as companies...
Shell to Buy ARC Resources in $16.4 Billion Deal to Expand Canada Output
By Bill Pan Shell is set to buy ARC Resources in a move that would expand the British oil major’s...
White House to Hold Meeting on Security Protocols After Shooting, Official Says
By Jack Phillips White House chief of staff Susie Wiles will hold a meeting with the Secret Service and the...